Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Unicycive Therapeutics Inc. Common Stock
UNCY | US
6.98
USD-0.03
-0.43%
UNCY | US
Loading StockChartView...
About Unicycive Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/03/2026
Close
6.98
Open
7.03
High
7.09
Low
6.86
Unicycive Therapeutics Inc. a biotechnology company engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494 which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos California.
View LessUNCY | US
Risk
49.1
Sharpe
0.15
Luna's Score
48/100
Recommendation
Hold
Luna says (UNCY | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
54.4%1 month
49.1%3 months
68.2%6 months
65.5%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.89
Debt to equity
-3.15
Debt to assets
1.05
Ent. to EBITDA
-1.03
Ent. to rev.
47.00
PEG
-
Other Fundamentals
EBITDA
-28.84M
MarketCap
658.61M
MarketCap(USD)
658.61M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-121.76
Short ratio
0.60
Short perc.
1.14
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.74
Range1M
1.07
Range3M
1.94
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.42
Price X volume
1.38M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.03 | 0.53 | Cheaper |
| Ent. to Revenue | 47.00 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.89 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 68.16 | 72.80 | Par |
| Debt to Equity | -3.15 | -1.23 | Cheaper |
| Debt to Assets | 1.05 | 0.25 | Expensive |
| Market Cap | 658.61M | 3.66B | Emerging |
